The Drug Repurposing Service Providers Market Is Estimated To Be Worth USD 1.2 Billion In 2030, Predicts Roots Analysis

>

The drug repurposing service providers market is estimated to be worth USD 1.2 billion in 2030, predicts Roots Analysis

Drug repurposing enables drug developers to optimize on past efforts and expenditure, thereby, offering a viable life cycle management strategy for marketed products and opportunities to re-evaluate failed / shelved drug development programs

 

Roots Analysis is pleased to announce the publication of its recent study, titled, “Drug Repurposing Service Providers Market, 2020-2030.”

 

The report features an extensive study of the current market landscape and future opportunities for players offering services for repurposing / repositioning / reprofiling of drug candidates. It features an in-depth analysis, highlighting the capabilities of various service providers engaged in this domain. In addition to other elements, the study includes:

  • A detailed assessment of the current market landscape of companies offering drug repurposing services. 
  • Elaborate profiles of key players that specialize in offering services for the development of repurposed drugs.
  • An analysis of the partnerships that have been established in this domain, in the recent past.
  • An analysis of the initiatives of big biopharma players engaged in this domain.
  • A detailed analysis of more than 1,700 terminated / withdrawn / suspended clinical studies of the drug candidates.
  • A detailed analysis on the cost saving potential of drug repurposing approaches, as compared to the traditional de novo drug development methods.
  • A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
  • Type of Repurposing Approaches
  • Disease-centric approach
  • Target-centric approach
  • Drug-centric approach
  • Therapeutic Area
  • Same Therapeutic Area
  • Different Therapeutic Area
  • Type of Drug Molecule
  • Biologics 
  • Small Molecule
  • Key Geographical Region 
  • North America
  • Europe
  • Asia-Pacific

 

Key companies covered in the report

  • Auxillis Pharma
  • ChemBio Discovery Solutions
  • Excelra
  • GVK Bio
  • Iris Pharma
  • Lantern Pharma
  • PanXome
  • Pharmacelera
  • Physiogenex
  • Smart Pharma
  • Socium
  • SOM Biotech

 

For more information please click on the following link:

https://www.rootsanalysis.com/reports/drug-repurposing-service-provides.html

 

Other Recent Offerings

  1. Peptides and Macrocycle Drug Discovery: Services and Platforms Market, 2020 - 2030
  2. China Biopharmaceutical Contract Manufacturing Market, 2020-2030
  3. Antibody Contract Manufacturing Market, 2020 - 2030

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

 

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

 

Share:

Keywords: roots analysis,research,pharma,biotech,analysis,market research,industry reports,business report,global

Comments

Other related blogs

The customers who need to purchase the compartments

By : JK Rowling CBD Gummies

  JK Rowling CBD Gummies The customers who need to purchase the compartments of JK Rowling CBD..


The customers who need to purchase the compartments

By : JK Rowling CBD Gummies

  JK Rowling CBD Gummies The customers who need to purchase the compartments of JK Rowling CBD..


How To Buy An MTP Abortion Pill Kit Online?

By : Privacypillrx

Medication abortion is the process of terminating a pregnancy in the early stage with help of aborti..


The RNAi therapeutics market is anticipated to grow at an annualized rate of more than 45%, till 2030, claims Roots Analysis

By : Roots Analysis

The recent approval of first RNAi therapeutic, ONPATTROTM, has caused a surge in interest of the ind..